BLEOMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Bleomycin patents expire, and what generic alternatives are available?
Bleomycin is a drug marketed by Cipla, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, Pharmachemie Bv, Teva Parenteral, and Teva Pharms Usa. and is included in eight NDAs.
The generic ingredient in BLEOMYCIN is bleomycin sulfate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bleomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bleomycin
A generic version of BLEOMYCIN was approved as bleomycin sulfate by HOSPIRA on March 10th, 2000.
Summary for BLEOMYCIN
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BLEOMYCIN |
DailyMed Link: | BLEOMYCIN at DailyMed |
US Patents and Regulatory Information for BLEOMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipla | BLEOMYCIN SULFATE | bleomycin sulfate | INJECTABLE;INJECTION | 209439-001 | Mar 11, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hospira | BLEOMYCIN SULFATE | bleomycin sulfate | INJECTABLE;INJECTION | 065031-002 | Mar 10, 2000 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hikma | BLEOMYCIN SULFATE | bleomycin sulfate | INJECTABLE;INJECTION | 065042-002 | Oct 17, 2001 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Parenteral | BLEOMYCIN SULFATE | bleomycin sulfate | INJECTABLE;INJECTION | 064084-002 | Jun 1, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |